Related Experiment Video

Updated: Jan 6, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

6.3K

Pembrolizumab as a treatment for PML? Waiting for Godot

Renaud A Du Pasquier1

  • 1From the Division of Neurology, Department of Clinical Neurosciences, University Hospital of Lausanne, University of Lausanne, Switzerland. renaud.du-pasquier@chuv.ch.

Neurology(R) Neuroimmunology & Neuroinflammation
|October 11, 2019
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Related Experiment Videos

Last Updated: Jan 6, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

6.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

916
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
916

Articles linked to this work by shared authors, journal, and citation graph.

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2026

Unraveling Microstructural and Macrostructural Brain Age Dynamics in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2025

Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis Cohort.

Neurology. Clinical practice·2025

Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2025

Advances in assessment and cognitive neurorehabilitation of HIV-related neurocognitive impairment.

Brain communications·2024

Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2024

Clinical Prognostic Factors Associated With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Multicenter Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2026

Pregnancy Exposure to Anti-CD20 Monoclonal Antibodies in Patients With Multiple Sclerosis: Results From an Italian Multicenter Registry Study.

Neurology(R) neuroimmunology & neuroinflammation·2026

The Gut Microbiome in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Distinct Multiomic Signatures of Environmental Exposure Drive Immune Dysregulation and Disease Activity in Early Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Myelin Oligodendrocyte Glycoprotein Antibodies in Breast Milk in a Lactating Woman With Severe Enterovirus-Associated MOGAD.

Neurology(R) neuroimmunology & neuroinflammation·2026

Long-Term Outcomes in Autoimmune Encephalitis: A Nationwide, Clinical Study in Denmark.

Neurology(R) neuroimmunology & neuroinflammation·2026

Biologic Therapy for Severe Asthma: Biomarker-Guided Precision Treatment and Immunopathological Mechanisms.

Journal of visualized experiments : JoVE·2026

Discovery and development of a bispecific antibody for the treatment of hemophilia.

Proceedings of the National Academy of Sciences of the United States of America·2026

A patient-derived missense mouse model of Kabuki syndrome 1.

Disease models & mechanisms·2026

Residual HIV activity and host immunometabolic remodeling during antiretroviral therapy: implications for cardiovascular-kidney-metabolic risk.

Frontiers in immunology·2026

Correction: Coexisting PTEN and SDHB mutations in a pediatric patient with PTEN hamartoma tumor syndrome: a case report.

Frontiers in pediatrics·2026

Atogepant modulates brain connectivity in episodic migraine: a longitudinal exploratory fMRI study.

Frontiers in neurology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us